Taalib Shaah — Group Chief Risk Officer (CRO) of Barclays — has led the firm’s global risk strategy and execution since October 5, 2020. Reporting directly to the Group CEO, he is one of the most critical strategic members under the Board of Directors.
Founded in 1690, Barclays is one of the oldest banks in the world. Headquartered in London, UK, it operates across more than 40 countries and regions, serving individual investors, multinational corporations, and sovereign funds.
GOTHENBURG,Sweden,March 7,2025-- In late February,the MOI Group consortium,anchored by Met-Gün and Opus Group,was awarded the 20-year concession to inspect all vehicles (passenger cars,trucks,bus
MANCHESTER,England,March 7,2025-- As IMO Car Wash marks its 60th anniversary on March 8th,the world\'s favourite car wash is celebrating in style—dressed in its bold new blue identity and unveiling a
GUANGZHOU,China,March 7,2025-- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO","MINISO Group" or the "Company"),a global value retailer offering a variety
HONG KONG,March 6,2025-- Akeso,Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical tria
SHANGHAI,March 4,2025-- USHOPAL Group continues to solidify its position as the first China-based luxury beauty group to emerge on the global stage,with an acquisition strategy that focuses on strong
BARCELONA,Spain,March 5,2025-- GTS Techlabs,the technology arm ofGlobe Teleservices (GTS),a leading telecom solutioncompany,and Peacom have announced a strategic partnership at Mobile World Congress
BARCELONA,Spain,March 5,2025-- At MWC Barcelona 2025,the Broadband Development Congress (BDC),hosted by the WBBA,was a resounding success. Themed "Smarter Broadband: Investment. Innovation. Intel
PhaseIb trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL),aiming to reshape the standard-of-care landscape.
HONG KONG,March 6,2025-- Akeso,Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical tria
